BMSSC
ACAD icon

B. Metzler seel. Sohn & Co’s Acadia Pharmaceuticals ACAD Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31,405
Closed -$483K – 751
2024
Q3 		$483K Hold
31,405
– – ﹤0.01% 648
2024
Q2 		$510K Hold
31,405
– – ﹤0.01% 631
2024
Q1 		$581K Buy
+31,405
New +$778K 0.01% 601

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

B. Metzler seel. Sohn & Co's ACAD Position: Q4 2024 in Review

B. Metzler seel. Sohn & Co sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 31,405 shares — an estimated $483K sold.

B. Metzler seel. Sohn & Co first reported a position in ACAD in Q1 2024 and held it in 3 quarters. The position peaked at $581K in Q1 2024. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

  • B. Metzler seel. Sohn & Co reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 31,405 Acadia Pharmaceuticals shares in Q4 2024, an estimated $483K.
  • B. Metzler seel. Sohn & Co first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • B. Metzler seel. Sohn & Co's Acadia Pharmaceuticals position peaked at $581K in Q1 2024.
  • 296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q4 2024, filed 12 Feb 2025.